Balsalazide

Introduction Overview

Generic Name

balsalazide

Brand Name

Colazal

Dosage Form

Oral capsules and tablets

Drug Class

5-aminosalicylates

Pharmacokinetics

Absorption:
Balsalazide is an oral prodrug designed to deliver the active moiety, 5-aminosalicylic acid (5-ASA), directly to the colon. Upon oral administration, balsalazide exhibits minimal systemic absorption as the intact drug passes through the stomach and small intestine. The drug is formulated to resist early absorption and deliver 5-ASA to the distal colon where it is needed in ulcerative colitis. The azo bond linking balsalazide to the inert carrier molecule is cleaved by colonic bacterial azoreductases, releasing 5-ASA locally in the colon. This targeted release minimizes systemic exposure and reduces systemic side effects.

Distribution:
Due to its minimal systemic absorption, balsalazide distributes poorly into systemic circulation. The active metabolite, 5-ASA, after colonic release may undergo limited absorption, thereafter binding variably to plasma proteins such as albumin. Consequently, plasma concentrations of 5-ASA achieved after balsalazide administration are generally low, reducing potential systemic toxicity. The local colonic distribution is the primary therapeutic site, and drug levels in colon tissue have demonstrated effective anti-inflammatory activity.

Metabolism:
Balsalazide itself is not extensively metabolized by human enzymes systemically but undergoes cleavage by bacterial azo reductases in the colon, releasing 5-ASA and an inert carrier molecule, 4-aminobenzoyl-beta-alanine. After the release, 5-ASA undergoes further metabolism via oxidation and acetylation in intestinal mucosal cells and liver, producing inactive metabolites such as N-acetyl-5-ASA. Metabolic activity varies among patients and influences individual response and tolerability. Factors such as colonic flora composition can affect the extent and rate of balsalazide cleavage.

Elimination:
The inactive metabolites formed from 5-ASA are primarily eliminated renally. The excretion of balsalazide unchanged is minimal due to its poor systemic absorption. The majority of the dosage is excreted fecally as unabsorbed drug or inactive metabolites produced by colonic bacteria. Renal elimination of N-acetylated metabolites requires intact kidney function, and impairment can prolong metabolite half-life. Balsalazide's elimination half-life for 5-ASA is approximately 30 minutes to 2 hours, depending on individual metabolism and renal clearance. Dose adjustments are rarely required but monitoring is advised in renal dysfunction.

Dosage Forms

Available Dosage Forms:
Colazal is available in oral delayed-release capsule and tablet formulations designed for targeted delivery of balsalazide to the colon. Specifically, the capsules contain balsalazide in a coated form to allow release in the colon.

Dosages for Adults and Adolescents:
- For active mild to moderate ulcerative colitis in adults and children aged 5 years and older, the usual total daily dose of balsalazide is 6.75 grams, divided into three doses of 2.25 grams each.
- The treatment duration typically ranges from 8 to 12 weeks, depending on clinical response.
- Tablets (Colazal) are indicated for adults 18 years and older; capsules may be administered in children 5 years and above.
- If capsules cannot be swallowed whole, patients may open them and sprinkle the contents onto applesauce for immediate ingestion.

Specific Patient Populations:
- Pediatric Use: Capsules are safe for children 5 years and older; however, tablets should not be given to anyone under 18 years.
- Hepatic and Renal Impairment: Although specific dose adjustments are not well established, caution is advised in patients with significant hepatic or renal dysfunction due to altered drug metabolism and elimination.
- Sodium Content: Tablets contain sodium; thus, patients on sodium-restricted diets should consult their physician before use.
- Pregnancy and Lactation: There is limited data on safety; benefits should be weighed against potential risks especially in pregnant and breastfeeding women.

Note: The exact milligram amounts per capsule or tablet vary by manufacturer and formulation; prescribing information should be consulted for specific product strengths.

Mechanism Of Action

Balsalazide is a prodrug that delivers 5-aminosalicylic acid (5-ASA) directly to the colon, the primary site of inflammation in ulcerative colitis. The azo bond of balsalazide is cleaved by azoreductase enzymes produced by colonic bacteria, releasing 5-ASA locally. This targeted release allows 5-ASA to exert its therapeutic effects with minimal systemic absorption and toxicity.

5-ASA acts mainly by modulating inflammatory processes in the colonic mucosa. It inhibits cyclooxygenase and lipoxygenase enzymes, thereby reducing the synthesis of pro-inflammatory prostaglandins and leukotrienes. This leads to decreased mucosal inflammation, edema, and epithelial injury. Additionally, 5-ASA has antioxidant properties, scavenging free radicals that contribute to chronic inflammation and tissue damage.

At the cellular level, 5-ASA suppresses the activation of nuclear factor-kappa B (NF-κB), a transcription factor central to the expression of multiple inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukins, and adhesion molecules. By limiting NF-κB signaling, balsalazide reduces recruitment and activation of inflammatory cells in the colonic mucosa. It also inhibits production of interleukin-1 (IL-1) and tumor necrosis factor, mediators implicated in the pathogenesis of ulcerative colitis.

Compared to related 5-aminosalicylates like mesalamine, balsalazide's unique azobond prodrug design improves colonic delivery and reduces systemic side effects. Clinical studies have demonstrated its efficacy in inducing remission and maintaining remission in mild to moderate ulcerative colitis. Its mechanism enables localized anti-inflammatory action while minimizing systemic exposure, which is crucial in the chronic management of inflammatory bowel disease.

Pharmacological Actions

Prodrug delivering 5-aminosalicylic acid selectively to the colon through bacterial azo bond cleavage.
Inhibits cyclooxygenase and lipoxygenase pathways, decreasing inflammatory prostaglandins and leukotrienes.
Scavenges reactive oxygen species, providing antioxidant effects to reduce oxidative tissue injury.
Suppresses activation of nuclear factor-kappa B, decreasing pro-inflammatory cytokine transcription.
Reduces inflammatory mediators including tumor necrosis factor-alpha and interleukins in colonic mucosa.
Exerts localized anti-inflammatory effects with minimal systemic absorption, reducing systemic toxicity.
Improves mucosal healing and reduces clinical symptoms of ulcerative colitis.
Maintains remission in mild to moderate ulcerative colitis by controlling inflammatory processes.
Has negligible effects on systemic immune function or systemic inflammation markers.
Acts primarily in the colonic lumen where its activation and therapeutic effect are localized.

Therapeutic Or Clinical Uses

Induction of remission in mild to moderate active ulcerative colitis in adults.
Maintenance therapy to sustain remission of ulcerative colitis to prevent flare-ups.
Treatment of mild to moderate ulcerative colitis in pediatric patients aged 5 years and older (capsule formulation).
Management of inflammatory symptoms such as abdominal pain, diarrhea, and rectal bleeding associated with ulcerative colitis.
Treatment option for patients intolerant or unresponsive to other 5-aminosalicylates.
Adjunct therapy in combination with other agents for comprehensive management of inflammatory bowel disease.
Suitable for patients requiring targeted colonic delivery of 5-ASA with reduced systemic side effects.
Effective in reducing histologic inflammation and promoting mucosal healing.
Potential off-label use in other idiopathic inflammatory colitis conditions under clinical supervision.
Used as an alternative to mesalamine in cases of hypersensitivity or intolerance.

Side Or Adverse Effects

Commonly reported headache occurring during therapy.
Mild to moderate gastrointestinal symptoms including nausea, vomiting, stomach pain, and diarrhea.
Joint pain or arthralgia reported occasionally.
Mild fever or flu-like symptoms including cold-like symptoms such as stuffy nose, sneezing, and sore throat.
Signs of allergic reactions such as hives, swelling of face, lips, tongue, or throat necessitating immediate medical attention.
Potential exacerbation of colitis symptoms including increased abdominal cramps, bloody diarrhea, and fever.
Possible kidney-related adverse effects such as decreased urination, swelling, or rapid weight gain indicative of renal impairment.
Liver dysfunction manifested by upper abdominal pain, dark urine, clay-colored stools, jaundice, and loss of appetite.
Hematologic side effects like anemia causing pale skin, fatigue, light-headedness, or shortness of breath may occur rarely.
Tooth or tongue discoloration (yellow or orange) if capsule contents are mixed with food and not swallowed promptly.
Rare systemic hypersensitivity reactions including severe rash or Stevens-Johnson syndrome reported very infrequently.
Abnormal liver function tests observed occasionally; monitoring advised during therapy.
Potential hypersensitivity with aspirin or other salicylate cross-reactivity.
Gastrointestinal intolerance leading to discontinuation in some patients.
Possible elevation of serum creatinine or parameters indicating nephrotoxicity; renal function monitoring recommended.

Precautions

Avoid use in patients with known hypersensitivity to balsalazide, mesalamine, aspirin, or other salicylates.
Use with caution in patients with impaired renal function or kidney disease; monitor renal parameters regularly.
Exercise caution in patients with liver disease; periodic liver function monitoring is recommended.
Consider sodium content when prescribing tablets to patients on sodium-restricted diets.
Inform healthcare providers of all medical conditions and medications to avoid potential drug interactions.
During pregnancy, weigh the benefits of treatment against risks; active colitis may adversely affect pregnancy outcomes.
Breastfeeding mothers should monitor nursing infants for diarrhea or adverse effects.
Avoid abrupt discontinuation without medical advice, particularly during active disease flare-ups.
Do not use in pediatric patients under 5 years for capsules or under 18 years for tablets.
If unable to swallow capsules whole, mix contents with applesauce and ingest immediately to avoid mucosal staining.
Monitor for signs of worsening colitis symptoms such as increased abdominal pain and bloody diarrhea.
Advise patients to seek medical attention if signs of allergic or severe adverse reactions develop.
Use caution in patients with pyloric stenosis or other gastrointestinal narrowing disorders.
Assess renal and hepatic function periodically during prolonged therapy.
Educate patients on proper administration, storage, and adherence to prescribed treatment duration.

Warnings

Risk of serious hypersensitivity and allergic reactions requiring immediate medical intervention.
Potential worsening of colitis symptoms despite therapy; necessitates prompt medical evaluation.
Monitor for nephrotoxicity: watch for reduced urine output, edema, or sudden weight gain.
Hepatotoxicity risk manifesting as elevated liver enzymes or clinical jaundice.
Anemia or blood dyscrasias may occur; baseline and follow-up hematologic evaluation recommended.
Avoid use in patients allergic to salicylates, aspirin, or related compounds.
Capsules should be swallowed whole to prevent mucosal staining and ensure proper delivery.
Use cautiously in populations with sodium restrictions due to sodium content in tablet formulations.
Inform patients not to take more than prescribed dose and to avoid double dosing.
Potential interaction with other drugs affecting renal or hepatic clearance; careful monitoring required.
Advise patients to report any unusual symptoms including rash, fever, or unexplained bruising.
Discontinue therapy if severe adverse effects or allergic reactions occur.
Use with caution in patients with coexisting gastrointestinal conditions that may impede drug delivery.
Ensure patients understand the importance of adhering to treatment duration (commonly 8-12 weeks).
Medical supervision is crucial during therapy to detect and manage adverse events promptly.

Contraindication

Known hypersensitivity or allergy to balsalazide, mesalamine, or other 5-aminosalicylates.
History of hypersensitivity reactions to aspirin or any other salicylates, including drugs such as Pepto-Bismol and Trilisate.
Patients with allergic or anaphylactic reactions to components of the medicine.
Individuals with severe renal impairment without close medical monitoring.
Patients with known severe hepatic disease unless potential benefits outweigh the risks.
Use is contraindicated in individuals with pyloric stenosis where capsule passage may be impaired.
Avoid in patients who have experienced serious skin reactions to mesalamine or related compounds.
Contraindicated in patients with unexplained anemia unless determined unrelated to the drug therapy.
Use is not recommended in children under 5 years for capsules and under 18 years for tablets due to safety and efficacy data limitations.
Patients with severe gastrointestinal obstructions that may prevent delivery of the active drug to the colon.

Drug Interactions

Concurrent use with other salicylate-containing products (aspirin, Pepto-Bismol) may increase risk of adverse effects or hypersensitivity reactions.
Potential interactions with nephrotoxic medications may exacerbate renal impairment; monitor renal function closely.
Drugs altering liver enzyme activity could affect metabolism of 5-ASA metabolites, potentially altering efficacy or toxicity.
Concomitant use with anticoagulants (e.g., warfarin) may enhance bleeding risk; careful monitoring of coagulation parameters is advised.
Co-administration with immunosuppressants or corticosteroids requires clinical vigilance for additive immunomodulatory effects.
Nonsteroidal anti-inflammatory drugs (NSAIDs) may increase gastrointestinal ulceration risk when combined with balsalazide.
Concomitant use with diuretics may warrant monitoring for electrolyte imbalances, given sodium content in some formulations.
Interactions with antacids or proton pump inhibitors have not shown clinically significant effects but should be assessed individually.
Potential interference with laboratory tests (e.g., urine 5-ASA levels) should be considered when monitoring therapy.
Herbal supplements with anti-inflammatory or immunomodulatory properties may potentiate or antagonize balsalazide effects.
Caution when used with drugs metabolized by pathways affected by intestinal flora or liver metabolism.
No significant interactions identified with vitamins or common over-the-counter medications, but clinical judgment advised.
Concurrent use with nephrotoxic or hepatotoxic agents necessitates periodic monitoring of organ function.
Patients should inform healthcare providers about all medications, including herbal and OTC products.
Clinicians should utilize drug interaction screening tools to identify and manage potential risks.

Preparations Of The Drug

Oral delayed-release capsules containing balsalazide, designed for colonic delivery via azo bond cleavage.
Oral tablets formulation (Colazal brand) suitable for adult patients, containing sodium as an excipient.
Capsule dosage forms suitable for pediatric patients aged 5 years and older.
Formulations supplied in blister packs or bottles for outpatient prescription use.
Available in strengths delivering approximately 750 mg to 1.5 g per capsule/tablet depending on preparation.
Packaging designed to protect drug from moisture and heat; store at room temperature.
Instructions for administration include swallowing capsules whole or opening and mixing with applesauce if needed.
Formulations free from systemic absorption enhancers, focusing on local release at colonic site.
Some preparations include inactive constituents such as coloring agents, binders, and fillers to optimize stability and patient acceptability.
Generic versions of balsalazide may be available, subject to regulatory approvals and local availability.
Drug labeling includes comprehensive patient information leaflets for safe and effective use.
Bulk powder forms are not commercially available; drug marketed primarily as oral capsules and tablets.
Reformulations under investigation may include novel delivery systems aiming to improve mucosal targeting.
Storage and handling instructions emphasize keeping medicine out of the reach of children.
Patient education materials accompany the medication to promote adherence and inform about potential side effects.